Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus

被引:47
作者
Chen, Quanjiao [1 ,2 ]
Kuang, Haimen [3 ]
Wang, Huadong [1 ]
Fang, Fang [3 ]
Yang, Zhongdong [4 ]
Zhang, Zhiping [1 ]
Zhang, Xianen [1 ]
Chen, Ze [1 ,3 ,4 ]
机构
[1] Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Hubei, Peoples R China
[2] Chinese Acad Sci, Grad Univ, Beijing 100049, Peoples R China
[3] Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China
[4] Shanghai Inst Biol Prod, Shanghai 200052, Peoples R China
关键词
H5N1; Hemagglutinin; Neuraminidase; Matrix protein; Nucleoprotein; DNA vaccine; A VIRUS; BALB/C MICE; IN-VIVO; NUCLEOPROTEIN; VACCINE; IMMUNIZATION; INFECTION; IMMUNITY; HEMAGGLUTININ; GENE;
D O I
10.1007/s11262-008-0305-2
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Avian influenza has been regarded as a human health threat. A major measure to prevent its outbreak is vaccination. In this study, a series of expression plasmids carrying the hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), matrix protein 1 (M1), and matrix protein 2 (M2) genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were constructed. These plasmids were administered to mice by electroporation (50 mu g for each per administration, 1-5 times, at an interval of 2 weeks), and the mice were challenged with the homologous virus later. The mice immunized with HA plasmid once and the NA plasmid twice survived 100%, and those with NP plasmid showed 60-80% survival rate with at least three immunizations. The mice immunized with M1 plasmid survived 25% with five immunizations, while M2 plasmid had no protection even with five immunizations. The mixture of M1 and NP plasmids protected 95% of the mice against the homologous virus, and 80% of the mice against a challenge with heterologous H1N1 (PR8) virus. Moreover, the homologous protection lasted at least 6 months. Our data provided a basis for selecting multiple-component AIV vaccines.
引用
收藏
页码:30 / 38
页数:9
相关论文
共 36 条
[31]   Protection against influenza virus challenge by topical application of influenza DNA vaccine [J].
Watabe, S ;
Xin, KQ ;
Ihata, A ;
Liu, LJ ;
Honsho, A ;
Aoki, I ;
Hamajima, K ;
Wahren, B ;
Okuda, K .
VACCINE, 2001, 19 (31) :4434-4444
[32]  
Webster R., 2002, WHO manual on animal influenza diagnosis and surveillance: World Health Organization, Department of Communicable Disease Surveillance and Response
[33]   EVOLUTION AND ECOLOGY OF INFLUENZA-A VIRUSES [J].
WEBSTER, RG ;
BEAN, WJ ;
GORMAN, OT ;
CHAMBERS, TM ;
KAWAOKA, Y .
MICROBIOLOGICAL REVIEWS, 1992, 56 (01) :152-179
[34]   Focus on research: H5N1 influenza - Continuing evolution and spread [J].
Webster, Robert G. ;
Govorkova, Elena A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (21) :2174-2177
[35]   Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid [J].
Xie, Hang ;
Liu, Teresa ;
Chen, Hong ;
Huang, Xiaoyuan ;
Ye, Zhiping .
VACCINE, 2007, 25 (44) :7649-7655
[36]   INFLUENZA-A VIRUS NUCLEOPROTEIN IS A MAJOR TARGET ANTIGEN FOR CROSS-REACTIVE ANTI-INFLUENZA-A VIRUS CYTO-TOXIC LYMPHOCYTES-T [J].
YEWDELL, JW ;
BENNINK, JR ;
SMITH, GL ;
MOSS, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (06) :1785-1789